Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal ...

VRDN-008 is a half-life extended bispecific FcRn inhibitor comprising an Fc fragment and an albumin-binding domain designed to prolong IgG suppression and provide a potentially best-in-class ...

VRDN-008 is a half-life extended bispecific FcRn inhibitor comprising an Fc fragment and an albumin-binding domain designed to prolong IgG suppression and provide a potentially best-in-class ...

Albumin binding to FcRn, GP60, and SPARC results in an improved PK profile, decreased toxicity risk, and a broader therapeutic index preclinically, with significant targeting of the tumor ...

Nipocalimab binds FcRn with high specificity ... By modulating IgG levels without impacting albumin recycling or broader immune function, nipocalimab presents a targeted strategy for potentially ...

PMID: 20081867. 8. Andersen JT, Sandlie I. 2009. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics.

Immunovant’s IMVT-1402 is highlighted as the most convenient FcRn inhibitor in late-stage development, featuring an easy-to-use subcutaneous auto-injector. The drug’s potential for deeper IgG ...

In order to address the above issue, it is desirable to screen fatty acid derivatives with low binding affinity to FABP but high binding affinity to albumin. FIGURE 4. Different modification approach ...

The binding affinity of the Fc fragment towards FcRn (FCGRT&B2M) would help forecast the half-life of the antibody, while that between the Fc fragment and FcγRIIIa (CD16a) would impact the ...